Summary: RET has recently been identified as a potential new oncogenic driver in a subset of patients with non–small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer. Cancer Discov; 3(6); 604–6.
No takes yet. Share an insight, caveat, or question.
Gainor et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: